CAR-T

CAR-T therapy
#Allogene Therapeutics #Autoimmune disease #CAR-T #Cell therapy #Phase I trial

First clinical data for allogeneic CAR-T in autoimmune disease

Allogene Therapeutics has reported preliminary safety, efficacy and translational data from the ongoing Phase I RESOLUTION study evaluating ALLO-329, an investigational, off-the-shelf allogeneic CAR-T product designed specifically for autoimmune disease.   The data were presented at the American College of Rheumatology (ACR) Convergence in Orlando, Florida. … Read More

#Editor's Choice #News

CAR-T in multiple myeloma
#CAR-T #Caribou Biosciences #Cell therapy #Haematology #Oncology

Caribou Biosciences cancels allogeneic CAR-T programmes

Caribou Biosciences has announced that it is discontinuing its two allogeneic CAR-T cell therapy programmes due to financing constraints.  It will discontinue development of vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. … Read More

#Cancer Research #News

CAR-T cells attack cancer cells
#CAR-T #Cell therapy #Generate Biomedicines #Oncology #Ovarian cancer

First human trials in ovarian cancer for ‘armoured’ CAR-T therapy

Roswell Park Comprehensive Cancer Center and Generate Biomedicines have dosed the first patient in a first-in-human clinical trial evaluating GB-5267, an autologous IL‑18–armoured CAR T-cell therapy.  The therapy is designed to overcome key barriers that have limited the success of cellular therapies in solid tumours.  … Read More

#Cancer Research #News #Trending News

CAR-T therapy
#CAR-T #Cell therapy #Circio Holding #circular RNAs #Financing

Circio raises NOK 200 million towards in vivo CAR-T programme

Circio Holding has successfully completed a private placement raising gross proceeds to the company of approx. NOK 200 ($21) million, through the allocation of 16,865,000 new shares.  The Offer Price corresponds to a 9% discount to the volume weighted average share price (VWAP) quoted for trade in the company's shares… Read More

#Business & Investment #News

CAR-T cell therapy
#Bristol Myers Squibb #CAR-T #Cell therapy #Clinical trials #Novartis

Novartis and BMS pause CAR-T trials due to safety concerns

Novartis and Bristol Myers Squibb (BMS) have both paused clinical trials of CAR-T cell therapies for lupus and other autoimmune diseases due to concerning safety findings.  Novartis has placed holds on trials of rapcabtagene autoleucel (rap-cel), stopping screening, randomisation, and treatment administration in trials in lupus, myasthenia… Read More

#News #Trending News

CAR-T in multiple myeloma
#CAR-T #Cell therapy #Clinical trial #HaemaLogiX #Oncology

KOALA trial launched to assess CAR-T for myeloma

The first patient has been dosed with PMCC-COE-KMA, an investigational CAR T-cell therapy being developed by Peter MacCallum Cancer Centre’s Centre of Excellence in Cellular Immunotherapy (CoE) and licensed by Australian biotechnology company HaemaLogiX.  The KOALA trial will evaluate the safety and efficacy of PMCC-COE-KMA in patients… Read More

#Cancer Research #News

Map of China
#CAR-T #Cell therapy #China #Oncology #Solid tumours

When the world’s first solid-tumour CAR-T gets approved in China

In June 2026, China's National Medical Products Administration cleared satricabtagene autoleucel (satri-cel), CARsgen's Claudin18.2 CAR-T, for advanced gastric cancer. It became the world's first CAR-T cell therapy approved for a solid tumour. The science is genuinely impressive. But the geography is the story. Satri-cel is not a Chinese drug that… Read More

#Exclusive Content #Opinion #Regulatory

CAR-T cells attack cancer cells
#CAR-T #Cell therapy #Oncology #Pancreatic cancer #The University of Texas at Austin

Research uncovers driver of CAR-T resistance in solid tumours

Pancreatic tumours can resist immunotherapy by recruiting nearby immune cells, according to new research, which has revealed a potential new strategy for overcoming resistance in cell therapies.  CAR T-cell therapy has transformed treatment for several blood cancers but has repeatedly stalled against solid tumours such as pancreatic… Read More

#Cancer Research #Editor's Choice #News

CAR-T cell attacking cancer
#CAR-T #Cell therapy #Eli Lilly #Mergers and acquisitions

Lilly buys in vivo CAR-T developer Kelonia Therapeutics

Eli Lilly has reached an agreement to acquire Kelonia Therapeutics, a clinical-stage biotechnology company pioneering in vivo gene delivery, for up to $7 billion.  Kelonia has developed a proprietary in vivo gene placement system (iGPS0) that uses specially engineered lentiviral-based particles designed to enter T-cells inside the body, allowing the… Read More

#Business & Investment #News

Cancer research
#Cancer Grand Challenges #Cancer immunotherapy #CAR-T #Childhood cancer #Clinical trial

Trial to test CAR T-cell therapies as childhood cancer cures 

A first-of-its-kind trial has launched to explore whether personalised CAR T-cell immunotherapy could treat childhood cancers. The clinical trial, taking place in the UK and US, has enrolled a group of 60 children with cancer and offered them access to personalised investigational therapies. Researchers hope these investigational therapies… Read More

#Cancer Research #Editor's Choice #News

CAR-T in multiple myeloma
#Biotech #Cancer research #CAR-T #Drug discovery #Oncology

The next generation of CAR-T cell therapies

Drug Discovery World Editor Reece Armstrong speaks to Dr Jan Davidson-Moncada, Chief Medical Officer at Imviva Biotech about the development of CAR-T cell therapies and the company’s activities in this space.   RA: What are the biggest challenges when developing CAR-T cell therapies?   JDM: CAR-T therapies face several formidable barriers. Autologous approaches made from a patient’s own T-cells are… Read More

#Exclusive Content

CAR-T in multiple myeloma
#Australia #CAR-T #Myeloma

TGA approves trial for first-in-human multiple myeloma therapy

Australia’s Therapeutic Goods Administration (TGA) has approved a first-in-human trial of a T-cell therapy in multiple myeloma.  The therapy, developed by HaemaLogiX in collaboration with the Peter MacCallum Cancer Centre (Peter Mac), is a KMA.CAR T-cell immunotherapy. The novel autologous CAR-T cell therapy targets Kappa Myeloma Antigen (KMA), a receptor found only on… Read More

#News #Regulatory

Gilead offices
#Advanced Therapies #Arcellx #CAR-T #Cell therapy #Gilead Sciences #Mergers and acquisitions

Gilead Sciences to acquire CAR-T company Arcellx

Gilead Sciences has entered into a definitive agreement to acquire Arcellx for an equity value of $7.8 billion.   Arcellx is a biotechnology company focused on delivering a new class of immunotherapies for patients with cancer and other incurable diseases.  The companies have an existing collaboration to co-develop and co-commercialise Arcellx’s… Read More

#Business & Investment #News #Trending News

CAR-T cells attacking a cancer cell
#Advanced Therapies #CAR-T #Cell therapy #Lyell Immunopharma #Lymphoma #Oncology #Phase III trial

CAR-Ts go head-to-head in first-of-its-kind clinical trial

Lyell Immunopharma has begun its PiNACLE – H2H Phase III trial evaluating rondecabtagene autoleucel (ronde-cel, also known as LYL314) compared to lisocabtagene maraleucel (liso-cel) or axicabtageneciloleucel (axi-cel).  The CAR-T therapies will be assessed in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) receiving treatment in the second-line… Read More

#Cancer Research #News #Trending News

CAR-T cell therapy
#Advanced Therapies #CAR-T #Clinical trial #Financing

Vyriad raises $85m to advance CAR-T candidate to clinic 

Biotechnology company Vyriad has closed the final $25 million tranche of its Series B financing round to advance the company’s in vivo CAR-T candidate to clinic.  VV169 has been developed by Vyriad for the treatment of patients with relapsed or treatment-refractory multiple myeloma. The treatment is one of the first in vivo CAR-T candidates leveraging Vyriad’s lentiviral platform, combining an… Read More

#Business & Investment #News